{"nctId":"NCT00376168","briefTitle":"A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease","startDateStruct":{"date":"2007-08"},"conditions":["Gaucher Disease"],"count":32,"armGroups":[{"label":"prGCD 30 Units/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)"]},{"label":"prGCD 60 Units/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Plant cell expressed recombinant glucocerebrosidase (prGCD)"]}],"interventions":[{"name":"Plant cell expressed recombinant glucocerebrosidase (prGCD)","otherNames":["Taliglucerase alfa"]},{"name":"Plant cell expressed recombinant glucocerebrosidase (prGCD)","otherNames":["Taliglucerase alfa"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females, 18 years or older\n* Confirmed enzymatic diagnosis of Gaucher disease\n* Splenomegaly defined as greater than eight times the expected volume (measured volume divided by estimated volume (0.2% of body weight)\\] as determined by MRI volumetric analysis\n* Female patients of child-bearing potential who agree to use a medically acceptable method of contraception\n* Thrombocytopenia (defined as platelet counts below the lower limit of normal) and/or anemia (defined by hemoglobin level at least 1 g/dL below normal range according to sex and age).\n* Patients who have not received ERT in the past or patients whoc have not received ERT in the past 12 months and have a negative anti-glucocerebrosidase antibody test.\n* Patients who have not received substrate reduction therapy (SRT) in the past 12 months.\n* Ability to provide a written informed consent.\n\nExclusion Criteria:\n\n* Currently taking another experimental drug for any condition\n* Pregnant or nursing\n* Presence of HIV and/or, HBsAg and/or hepatitis C infections\n* Presence of severe neurological signs and symptoms, defined as complete ocular paralysis, overt myoclonus or history of seizures, characteristic of neuronopathic Gaucher disease.\n* Previous anaphylactoid reaction to Cerezyme® or Ceredase®.\n* History of allergy to carrots.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Spleen Volume Measured by MRI.","description":"Calculated as percent change in spleen volume from Baseline to 9 months","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.91","spread":"7.79"},{"groupId":"OG001","value":"-38.01","spread":"9.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Liver Volume","description":"Calculated as percent change in liver volume from Baseline to 9 months","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.48","spread":"11.27"},{"groupId":"OG001","value":"-11.11","spread":"6.68"}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin","description":"Absolute change in Hemoglobin concentration from Baseline to Month 9","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"1.4"},{"groupId":"OG001","value":"2.2","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Change in Platelet Count","description":"Change in Platelet count from Baseline to Month 9","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11,427","spread":"20,214"},{"groupId":"OG001","value":"41,494","spread":"47,063"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Chitotriosidase","description":"Change in Chitotriosidase from Baseline to Month 9","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14,548","spread":"8,025.8"},{"groupId":"OG001","value":"-12,538","spread":"14,489"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":["Hypersensitivity","Headache","Abdominal pain","Feeling hot","Arthralgia"]}}}